Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, ...